Literature DB >> 26223194

MYC Analysis by Fluorescent In Situ Hybridization and Immunohistochemistry in Primary Adrenal Angiosarcoma (PAA): a Series of Four Cases.

Kristine M Cornejo1,2, Lloyd Hutchinson3, Maryann St Cyr3, Vania Nose4, Patrick J McLaughlin4, A John Iafrate4, Peter M Sadow4.   

Abstract

Primary adrenal angiosarcomas (PAA) are rare with 36 cases reported in the English literature. MYC protein expression and gene amplification have been detected in secondary angiosarcoma (AS), and a subset of primary AS. The aim of this study was to report the clinicopathologic features of PAA and examine these tumors for MYC amplification and protein expression in a small series of four cases (resection, n = 4). Three had available material for ancillary studies and were investigated for MYC gene abnormalities and protein expression using fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC), respectively. Tumors occurred in three females and one male with a mean age of 69 (53-75) years. The sizes ranged from 8.5 to 15 (mean 11.5) cm and were epithelioid in morphology. All tumors had prominent necrosis, and the mitotic count ranged from 4 to 41/10 high-power fields (HPFs) (mean 20/10 HPFs, ×400). Immunohistochemically, the tumor cells were positive for CD31 in 4/4 cases, CD34 in 1/4 cases, and cytokeratin in 4/4 cases. The mean follow-up period was 10.8 (3-19) months, of which three patients died of disease with distant metastases, and one patient was alive with disease. MYC nuclear staining was identified in the three cases tested. Two cases showed polysomy of chromosome 8 without MYC amplification or rearrangement. Two MYC-positive cases by IHC demonstrated copy number gain in chromosome 8, and one MYC-positive case was not associated with a chromosome 8/MYC gene abnormality. In the context of new targeted therapies, MYC positivity in PAA may be clinically valuable in treating patients with these aggressive neoplasms.

Entities:  

Keywords:  Adrenal; FISH; Immunohistochemistry; MYC; Polysomy; Primary angiosarcoma

Mesh:

Substances:

Year:  2015        PMID: 26223194     DOI: 10.1007/s12022-015-9385-4

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  52 in total

1.  MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome.

Authors:  Carl Morrison; Michael Radmacher; Nehad Mohammed; David Suster; Herbert Auer; Susie Jones; Judy Riggenbach; Nicole Kelbick; Gary Bos; Joel Mayerson
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

2.  Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites.

Authors:  Paula S Ginter; Juan Miguel Mosquera; Theresa Y MacDonald; Timothy M D'Alfonso; Mark A Rubin; Sandra J Shin
Journal:  Hum Pathol       Date:  2013-11-12       Impact factor: 3.466

3.  BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.

Authors:  Qiang Shao; Aarthi Kannan; Zhenyu Lin; Brendan C Stack; James Y Suen; Ling Gao
Journal:  Cancer Res       Date:  2014-10-02       Impact factor: 12.701

4.  Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.

Authors:  George Jour; John D Scarborough; Robin L Jones; Elizabeth Loggers; Seth M Pollack; Colin C Pritchard; Benjamin L Hoch
Journal:  Hum Pathol       Date:  2014-04-24       Impact factor: 3.466

5.  Primary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional combined tumor.

Authors:  Charlotte Lepoutre-Lussey; Audrey Rousseau; Abir Al Ghuzlan; Laurence Amar; Chantal Hignette; Angela Cioffi; Franck Zinzindohoué; Sophie Leboulleux; Pierre-François Plouin
Journal:  Eur J Endocrinol       Date:  2011-11-02       Impact factor: 6.664

6.  A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.

Authors:  Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki
Journal:  Cancer J       Date:  2005 May-Jun       Impact factor: 3.360

7.  Hemangiosarcoma of the adrenal glands: CT findings in two cases.

Authors:  F Ferrozzi; G Tognini; D Bova; G Zuccoli; P Pavone
Journal:  Abdom Imaging       Date:  2001 May-Jun

8.  Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience.

Authors:  Darya Buehler; Stephanie R Rice; John S Moody; Patrick Rush; Gholam-Reza Hafez; Steven Attia; B Jack Longley; Kevin R Kozak
Journal:  Am J Clin Oncol       Date:  2014-10       Impact factor: 2.339

9.  An unusual angiosarcoma. A case report.

Authors:  M K Al-Meshan; K C Katchy
Journal:  Med Princ Pract       Date:  2004 Sep-Oct       Impact factor: 1.927

10.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression.

Authors:  Troy A Baudino; Catriona McKay; Helene Pendeville-Samain; Jonas A Nilsson; Kirsteen H Maclean; Elsie L White; Ann C Davis; James N Ihle; John L Cleveland
Journal:  Genes Dev       Date:  2002-10-01       Impact factor: 11.361

View more
  3 in total

1.  Angiosarcoma of the Adrenal Gland Treated Using a Multimodal Approach.

Authors:  Jay G Fuletra; Benjamin T Ristau; Barton Milestone; Harry S Cooper; Alysia Browne; Sujana Movva; Thomas J Galloway; Randall Lee; Nikhil Waingankar; Alexander Kutikov
Journal:  Urol Case Rep       Date:  2016-12-01

2.  A case report of primary adrenal angiosarcoma as depicted on magnetic resonance imaging.

Authors:  Xue-Ming Li; Hong Yang; Jing Reng; Peng Zhou; Zhu-Zhong Cheng; Zhen Li; Guo-Hui Xu
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

3.  Case Report: Postoperative Recurrence of Adrenal Epithelioid Angiosarcoma Achieved Complete Response by Combination Chemotherapy With Liposomal Doxorubicin and Paclitaxel.

Authors:  Hangping Wei; Jie Mao; Yandan Wu; Qinfei Zhou
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.